Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $33.40 Average PT from Analysts

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) have earned an average rating of “Hold” from the seven brokerages that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $33.40.

PCRX has been the topic of several recent research reports. Weiss Ratings restated a “sell (d)” rating on shares of Pacira BioSciences in a report on Wednesday, October 8th. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Finally, Truist Financial upgraded Pacira BioSciences from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a report on Friday, July 25th.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $21.33 on Tuesday. The company has a current ratio of 2.38, a quick ratio of 1.91 and a debt-to-equity ratio of 0.50. Pacira BioSciences has a 1 year low of $16.00 and a 1 year high of $27.64. The business has a fifty day simple moving average of $25.01 and a 200 day simple moving average of $24.64. The firm has a market cap of $958.42 million, a price-to-earnings ratio of -7.67 and a beta of 0.40.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The business had revenue of $181.10 million during the quarter, compared to analyst estimates of $183.11 million. During the same period last year, the company earned $0.96 earnings per share. Pacira BioSciences’s quarterly revenue was up 1.7% compared to the same quarter last year. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Pacira BioSciences will post 2.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Marcelo Bigal sold 4,912 shares of the firm’s stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $23.67, for a total transaction of $116,267.04. Following the transaction, the director directly owned 11,393 shares in the company, valued at $269,672.31. This trade represents a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Pacira BioSciences

Several institutional investors have recently bought and sold shares of PCRX. GAMMA Investing LLC grew its position in shares of Pacira BioSciences by 112.8% in the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company’s stock valued at $92,000 after purchasing an additional 1,958 shares during the last quarter. Wealthquest Corp acquired a new stake in shares of Pacira BioSciences in the first quarter valued at about $59,000. Robeco Institutional Asset Management B.V. grew its position in shares of Pacira BioSciences by 18.2% in the first quarter. Robeco Institutional Asset Management B.V. now owns 82,694 shares of the company’s stock valued at $2,055,000 after purchasing an additional 12,750 shares during the last quarter. Illinois Municipal Retirement Fund grew its position in shares of Pacira BioSciences by 24.7% in the first quarter. Illinois Municipal Retirement Fund now owns 25,318 shares of the company’s stock valued at $629,000 after purchasing an additional 5,011 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Pacira BioSciences in the first quarter valued at about $277,000. 99.73% of the stock is currently owned by institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.